Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) insider Eric Warren sold 7,438 shares of the firm’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $28.12, for a total transaction of $209,156.56. Following the transaction, the insider owned 38,400 shares of the company’s stock, valued at approximately $1,079,808. This trade represents a 16.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Warren also recently made the following trade(s):
- On Friday, August 21st, Eric Warren sold 7,437 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $25.98, for a total value of $193,213.26.
- On Tuesday, July 21st, Eric Warren sold 7,438 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.87, for a total value of $199,859.06.
- On Friday, June 26th, Eric Warren sold 104,124 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $25.90, for a total value of $2,696,811.60.
Mineralys Therapeutics Trading Down 1.1%
Shares of MLYS opened at $26.59 on Friday. The business’s 50-day moving average price is $27.16 and its 200 day moving average price is $27.10. The company has a current ratio of 34.46, a quick ratio of 34.46 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $2.35 billion, a P/E ratio of -6.27 and a beta of 0.68. Mineralys Therapeutics, Inc. has a 1-year low of $22.30 and a 1-year high of $47.65.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on MLYS shares. Wall Street Zen cut shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Jefferies Financial Group reiterated a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Finally, Zacks Research raised Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, September 11th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $48.80.
Read Our Latest Research Report on Mineralys Therapeutics
Institutional Trading of Mineralys Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlueCrest Capital Management Ltd acquired a new position in Mineralys Therapeutics in the 2nd quarter valued at approximately $2,298,000. WINTON GROUP Ltd bought a new stake in shares of Mineralys Therapeutics in the 2nd quarter worth approximately $912,000. Arizona State Retirement System grew its holdings in shares of Mineralys Therapeutics by 22.4% during the 2nd quarter. Arizona State Retirement System now owns 15,357 shares of the company’s stock worth $414,000 after purchasing an additional 2,815 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Mineralys Therapeutics during the 2nd quarter worth approximately $333,000. Finally, Pale Fire Capital SE increased its position in shares of Mineralys Therapeutics by 68.0% during the second quarter. Pale Fire Capital SE now owns 614,284 shares of the company’s stock valued at $16,573,000 after purchasing an additional 248,658 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.
About Mineralys Therapeutics
Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney-related diseases. The company’s research is centered on conditions associated with excess aldosterone activity, including uncontrolled and resistant hypertension.
Mineralys’ lead investigational product is lorundrostat, also known as MLS-101, an oral, highly selective aldosterone synthase inhibitor. The company is evaluating lorundrostat in clinical studies as a potential treatment for patients whose blood pressure remains inadequately controlled despite existing therapy.
Featured Articles
- Five stocks we like better than Mineralys Therapeutics
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
